PI3K pathway activation in breast cancer
β
Elena LΓ³pez-Knowles; Sandra A. O'Toole; Catriona M. McNeil; Ewan K.A. Millar; Mi
π
Article
π
2009
π
John Wiley and Sons
π
French
β 552 KB
## Abstract Breast cancer is a common malignancy with current biological therapies tailored to steroid hormone (ER, PR) and HER2 receptor status. Understanding the biological basis of resistance to current targeted therapies and the identification of new potential therapeutic targets is an ongoing